MX2021003929A - Compuestos farmaceuticos. - Google Patents
Compuestos farmaceuticos.Info
- Publication number
- MX2021003929A MX2021003929A MX2021003929A MX2021003929A MX2021003929A MX 2021003929 A MX2021003929 A MX 2021003929A MX 2021003929 A MX2021003929 A MX 2021003929A MX 2021003929 A MX2021003929 A MX 2021003929A MX 2021003929 A MX2021003929 A MX 2021003929A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- tyk2 kinase
- compounds
- sup
- tyk2
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816369.1A GB201816369D0 (en) | 2018-10-08 | 2018-10-08 | Pharmaceutical compounds |
| PCT/EP2019/077118 WO2020074461A1 (en) | 2018-10-08 | 2019-10-07 | Tyk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003929A true MX2021003929A (es) | 2021-06-04 |
Family
ID=64397425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003929A MX2021003929A (es) | 2018-10-08 | 2019-10-07 | Compuestos farmaceuticos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12187716B2 (enExample) |
| EP (1) | EP3864009B1 (enExample) |
| JP (1) | JP7383030B2 (enExample) |
| KR (1) | KR102844196B1 (enExample) |
| CN (1) | CN113056456B (enExample) |
| AU (1) | AU2019359320B2 (enExample) |
| BR (1) | BR112021006424A2 (enExample) |
| CA (1) | CA3111049A1 (enExample) |
| DK (1) | DK3864009T3 (enExample) |
| ES (1) | ES3021420T3 (enExample) |
| FI (1) | FI3864009T3 (enExample) |
| GB (1) | GB201816369D0 (enExample) |
| IL (1) | IL281599B2 (enExample) |
| MX (1) | MX2021003929A (enExample) |
| PL (1) | PL3864009T3 (enExample) |
| PT (1) | PT3864009T (enExample) |
| SG (1) | SG11202102490TA (enExample) |
| WO (1) | WO2020074461A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005114D0 (en) * | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| GB1497536A (en) | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| BR0111754A (pt) | 2000-06-28 | 2003-04-29 | Astrazeneca Ab | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica |
| AU2479702A (en) | 2000-10-30 | 2002-05-15 | Janssen Pharmaceutica Nv | Tripeptidyl peptidase inhibitors |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| ATE465731T1 (de) | 2003-10-23 | 2010-05-15 | Ab Science | 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| CA2623327A1 (en) | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| WO2007131953A1 (en) | 2006-05-12 | 2007-11-22 | Ab Science | A new process for the synthesis of 2-aminoxazole compounds |
| US20090093452A1 (en) | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
| GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| US8367706B2 (en) | 2007-06-20 | 2013-02-05 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2278969B1 (en) | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2310384B1 (en) | 2008-07-09 | 2014-04-09 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| US20130096104A1 (en) | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| US20130143915A1 (en) | 2010-07-01 | 2013-06-06 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| SG11201401342VA (en) | 2011-10-12 | 2014-09-26 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| GB201202027D0 (en) | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| ES2566205T3 (es) | 2012-03-02 | 2016-04-11 | Sareum Limited | Inhibidores de quinasa TYK2 |
| KR101202026B1 (ko) | 2012-07-03 | 2012-11-16 | 민호현 | 황토 석부작 제조 방법 |
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| BR112016004723B1 (pt) * | 2013-09-03 | 2022-08-30 | Sareum Limited | Compostos de pirrolidina ou morfolina e composição contendo os mesmos |
| JP6310767B2 (ja) | 2014-05-13 | 2018-04-11 | 日本電子株式会社 | 自動分析装置及びノズル洗浄方法 |
| NO2721710T3 (enExample) | 2014-08-21 | 2018-03-31 | ||
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
-
2018
- 2018-10-08 GB GBGB1816369.1A patent/GB201816369D0/en not_active Ceased
-
2019
- 2019-10-07 EP EP19794095.0A patent/EP3864009B1/en active Active
- 2019-10-07 CA CA3111049A patent/CA3111049A1/en active Pending
- 2019-10-07 SG SG11202102490TA patent/SG11202102490TA/en unknown
- 2019-10-07 KR KR1020217013504A patent/KR102844196B1/ko active Active
- 2019-10-07 US US17/283,151 patent/US12187716B2/en active Active
- 2019-10-07 DK DK19794095.0T patent/DK3864009T3/da active
- 2019-10-07 PT PT197940950T patent/PT3864009T/pt unknown
- 2019-10-07 FI FIEP19794095.0T patent/FI3864009T3/fi active
- 2019-10-07 IL IL281599A patent/IL281599B2/en unknown
- 2019-10-07 BR BR112021006424A patent/BR112021006424A2/pt unknown
- 2019-10-07 ES ES19794095T patent/ES3021420T3/es active Active
- 2019-10-07 JP JP2021543577A patent/JP7383030B2/ja active Active
- 2019-10-07 WO PCT/EP2019/077118 patent/WO2020074461A1/en not_active Ceased
- 2019-10-07 MX MX2021003929A patent/MX2021003929A/es unknown
- 2019-10-07 PL PL19794095.0T patent/PL3864009T3/pl unknown
- 2019-10-07 CN CN201980066166.4A patent/CN113056456B/zh active Active
- 2019-10-07 AU AU2019359320A patent/AU2019359320B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GB201816369D0 (en) | 2018-11-28 |
| PT3864009T (pt) | 2025-04-23 |
| PL3864009T3 (pl) | 2025-04-22 |
| AU2019359320B2 (en) | 2024-04-04 |
| US12187716B2 (en) | 2025-01-07 |
| JP7383030B2 (ja) | 2023-11-17 |
| IL281599B2 (en) | 2024-10-01 |
| SG11202102490TA (en) | 2021-04-29 |
| ES3021420T3 (en) | 2025-05-26 |
| IL281599A (en) | 2021-05-31 |
| IL281599B1 (en) | 2024-06-01 |
| DK3864009T3 (da) | 2025-03-17 |
| CA3111049A1 (en) | 2020-04-16 |
| WO2020074461A1 (en) | 2020-04-16 |
| AU2019359320A1 (en) | 2021-03-18 |
| JP2022514799A (ja) | 2022-02-15 |
| KR102844196B1 (ko) | 2025-08-07 |
| CN113056456B (zh) | 2023-06-13 |
| KR20210076036A (ko) | 2021-06-23 |
| EP3864009A1 (en) | 2021-08-18 |
| BR112021006424A2 (pt) | 2021-07-06 |
| CN113056456A (zh) | 2021-06-29 |
| FI3864009T3 (fi) | 2025-03-24 |
| US20210387981A1 (en) | 2021-12-16 |
| EP3864009B1 (en) | 2025-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2020001776A (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
| GEAP202315746A (en) | Protein tyrosine phosphatase inhibitors | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| MA55145B1 (fr) | Polythérapie incluant un inhibiteur de kras g12c et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| MX2021004431A (es) | Procesos novedosos. | |
| MX2023009060A (es) | Antagonistas de gpr84 y usos de estos. | |
| PH12019500932A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| EA202090413A1 (ru) | Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы | |
| EA202090052A1 (ru) | Содержащие имидазол ингибиторы alk2 киназы | |
| MX379459B (es) | Inhibidores de bromodominios. | |
| EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| MX2023009059A (es) | Antagonistas de gpr84 y usos de estos. | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| MX2025001280A (es) | Antagonistas de gpr84 con piridona sustituidos y usos de estos | |
| MX2020013729A (es) | Compuestos de cianotriazol y usos de los mismos. |